Licensing · GCC · Announced 29 Jul 2026
Mabwell Bioscience → SaudiVax
Licensing deal between Mabwell Bioscience (China) and SaudiVax (Saudi Arabia), covering Aflibercept biosimilar, announced 29 Jul 2026. Value: Undisclosed.
Parties: Mabwell (Shanghai) Bioscience (China) → SaudiVax (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- GCC (Saudi Arabia as core hub, radiating regionally)
- Therapeutic area
- Ophthalmology
- Asset
- Aflibercept biosimilar — anti-VEGF biologic (reference: Eylea)
- Announced
- 29 Jul 2026
Our analysis
Why this matters
It's a localized biologic , not an imported one. The distinguishing feature here isn't the molecule, it's the structure: SVAX isn't just distributing Mabwell's aflibercept, it will manufacture it in the Kingdom.
Aflibercept (reference brand Eylea) is a high-value anti-VEGF biologic for retinal conditions — wet age-related macular degeneration and diabetic macular edema — and diabetic eye disease is a large, growing burden in a region with ~18–20% diabetes prevalence.
The full analysis is free to read with a work email on this page.
Source: Mabwell press release